Apogee Therapeutics, Inc. announced results from its Phase 1 clinical trial of APG777, covering data up to nine months, via a press release on October 24, 2024.
AI Assistant
APOGEE THERAPEUTICS INC
2024
8 K
Find Answers
Ask about any part of the document to get insights, explanations, or key details.